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ABSTRACT 
Peptide Deformylase (PDF) is an essential metalloenzyme and removes the formyl group from 
methionine at the N terminus of nascent polypeptide chains. Since this protein is essential for 
survival of most of the pathogenic bacteria and functionally equivalent gene is absent in 
mammalian cells, it provides an attractive target for development of novel antibacterials. In the 
current project, an In silico approach has been used to develop a novel broad spectrum 
antibacterial based on binding affinity of PDF with derivatives of hydrazines. Virtual screening 
and Molecular docking based on Lamarckian Genetic Algorithm was carried out to find binding 
affinity of PDFs from seven different pathogenic bacteria. These molecules were screened from 
PubChem database on the basis of structural similarity to sulfonylpiperidine. Molecular 
Dockings were carried out for each ligand and results were clustered together with accepted 
RMSD of 0.5 A
o
. Hydrogen bond analysis was done on UCSF Chimera while ADME and 
toxicity properties were evaluated using Molsoft and PreADMET server. 1-(4-fluorophenyl) 
sulfonylpiperidine-3-carbohydrazide (CID_4539974) was found to be the best potent inhibitor of 
PDF, made H-bonds with active metal binding amino residues, successfully passed the Lipinski 
rule of five, gained good drug-likeness model score, and exhibited negative carcinogenicity and 
toxicity test. Further, molecular dynamics simulation (MDS) was done to check the stability of 
protein-ligand complex under using GROMACSv4.05. Negative system energies of protein-
ligand complex, negligible deviation of Cα from crystal structure and decrease in fluctuations in 
region containing active metal binding amino acid residue supported the stability of protein-
ligand complex. The outcomes concluded that CID_4539974 have all the desirable properties to 
become a novel broad spectrum antibacterial by targeting bacterial PDF efficiently that needs 
further validation by wet lab experiments. 
Keywords: PDF, Sulfonylpiperidine, AutoDock, Docking, MDS.
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1. INTRODUCTION 
 
1.1 Introduction 
If we see in the past, we find that the life of human being is always endangered by infectious 
disease.  However, in the 21
st
 century prosperous societies live in fantasy that they are free from 
contagious diseases, moreover, if they any how attacked by pathogenic bacteria, there will be 
antibiotic to cure the disease. But, if we do not find alternatives to increasing antibiotic 
resistance, the present day scenario will be false. The discovery of antibiotics is one of the 
greatest findings of the 20
th
 century. At that time the infectious diseases were the leading cause 
of global fatality, the introduction of sulfa drugs and penicillin into medical use in 1930s and 
1940s respectively led to the treatment of infectious disease and decreased mortality rate [1].  
After the success of penicillin, intensive screening of antibacterial agents led to the discovery 
and successful clinical development of erythromycin, rifamycin, vancomycin, chloramphenicol, 
cephalosporin, tetracycline, streptomycin between 1940 and 1960 [2]. Despite all advances in the 
field, problems arise in the proven ability of bacteria to adapt and to develop resistance to 
multiple classes of existing antibiotics. Infectious diseases are still the second-leading cause of 
death worldwide and the third-leading cause of death in developed countries and become the 
global public health fear [3-4]. While a large group of antibacterials to conflict bacterial diseases 
are presently available, a number of frights have recently been raised on the need to develop new 
antibacterials. This need has arisen for several reasons; among them is the expansion of 
antibacterial resistant bacterial infections, rising of infectious diseases not yet recognized, re-
emerging of infectious disease experienced previously that have reappeared in more virulent 
forms and the consequential high and economic impact of infectious disease. The emergence of 
antibiotic resistance bacteria is a question of not “if,” but “when” will the antibiotic resistance 
occur. To get a sense of the seriousness of this matter, early resistance to multiple drugs was 
reported among the enteric bacteria, namely, Escherichia coli, Shigella and Salmonella, in the 
late1950s to early 1960s [5-7]. Recent resistance has been reported in the nosocomial S. aureus 
strains, both methicillin-resistant (MRSA) [8] and multidrug-resistance (MDR) [9]. It now seems 
that the emergence of antibiotic-resistant bacteria is inevitable to most every new drug. These 
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problems pose an urgent challenge to find new approach to combat these antibiotic resistant 
bacteria. To prevent the emergence and dissemination of resistant bacteria; continuing efforts to 
develop new antibacterial agents are needed i.e. by blocking or circumventing the resistance 
mechanism or identifying novel drug targets. 
 
1.2 Bacterial Diseases 
Bacterial diseases comprise any type of infection or illness caused by bacteria. They are 
microscopic organism and cannot be seen by naked eye. Millions of bacteria are normally 
inhabitant the human skin, intestine and genital parts. Most of the bacteria’s do not cause disease, 
however some are even good for health. Disease causing bacteria’s are called pathogenic bacteria 
and they cause infection by reproducing themselves with growth rate greater than that of good 
bacteria’s inside the body and producing toxins that damage the body. Some common bacteria 
and the types of disease they cause are- 
Leptospira interrogans belongs to obligate aerobe eubacteria family, with periplasmic flagella. 
It is sometimes transmitted to humans through contact with infected animal excretory product, 
either directly or in water. It invades directly through broken skin and may replicate in the liver 
and kidneys. Infection is thought as leptospirosis, which might be symptomless, a gentle non-
specific sickness, or end in death from liver harm and nephrosis (Weil's syndrome). 
Escherichia coli (E. coli) belongs to gram -ve, rod-shaped microorganism that's ordinarily found 
within the lower intestine organ of warm blooded organisms (endotherms). Most E. coli strains 
are harmless; however some serotypes will cause tract infection, serious food poisoning in 
humans. 
Enterococcus faecium is a Gram-positive, spherical cell that can found in pairs or chains alpha 
hemolytic or nonhemolytic bacterium in the genus Enterococcus. It can be commensal and can 
inhabitant within the human intestine; however it may also even be pathogenic, and inflicts 
diseases like surgical wound infection, nosocomial bacteremia, endocarditis, tract infections and 
neonatal meningitis. 
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Staphylococcus aureus is a member of the Firmicutes, and is usually inhabitant the human 
respiratory tract and skin. Disease-associated strains typically promote infections by 
manufacturing potent protein toxins. Also they express cell-surface proteins that bind and 
inactivate antibodies. Although S. aureus is not always pathogenic, it is frequent cause of 
respiratory illness, skin infections and sickness.  Moreover, the emergence of antibiotic-resistant 
forms of pathogenic S. aureus (e.g. MRSA) becomes a worldwide downside in clinical 
medication. 
Streptococcus mutans belongs to facultative anaerobes; gram-positive coccus-shaped 
microorganism ordinarily found within the human oral cavity and may be a vital contributor to 
dental caries. 
Pseudomonas aeruginosa is a common bacterium that may cause illness in animals, as well as in 
humans. They are gram-negative, asporogenous, rod-shaped, and monoflagellated bacteria that 
have a fantastic nutritionary versatility. The flexibility permits the organism to infect broken 
tissues or those with compromised immunity. The symptoms of infections are generalized 
inflammation and sepsis. If such colonizations occur in vital body organs, like the lungs, the 
urinary tract and kidneys, the results can be fatal. Because it can flourishes on variety of 
surfaces, this bacterium is also found on and in medical instrumentation, as well as catheters, 
inflicting cross-infections in hospitals and clinics. 
Vibrio cholerae belongs to family of Gram-negative bacteria and is comma-shaped with one, 
polar flagellum which helps in movement. There are some strains of V. cholerae, which are 
pathogenic in nature. Vibrio cholerae infects the human intestine and enhance mucous 
production, causes diarrhea and vomiting that lead to dehydration and finally death, if not 
treated. It is typically transmitted through the excreta of Associate in nursing infected person, 
usually by approach of unclean water or contaminated food. 
The examples discussed above are only few in thousands of pathogenic bacteria causing different 
types of diseases. Moreover the emergence of drug resistant bacteria raises the essential need for 
approaching computational method to reduce the time for discovering new drugs. 
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1.3 Computational Drug Discovery 
Computational drug discovery provides good strategy for fast and economizing drug discovery 
and development method. It minimizes time, efforts and cost of drug discovery and development. 
Recent advances in bioinformatics and impressive increase in the availability of both biological 
macromolecule and small molecule information has brought us too considerably nearer to 
computational drug discovery. 
In silico strategies will facilitate in distinguishing drug targets via bioinformatics tools. They will 
even be accustomed to identify the target proteins and analyze their structures for possible 
binding sites. In silico method help in production of candidate molecules, confirmation for their 
drug resemblance, docking of these molecules with the target protein, ordering them consistently 
with their binding energies affinity, and further optimizing the molecules to enhance binding 
characteristics. 
The utilization of complementary experimental and informatics techniques increases the prospect 
of success in several stages of the discovery procedure, from the identification of novel targets 
and revelation of their functions to the discovery and development of lead compounds with 
desired properties. Computational tools supply the benefit of delivering new drug candidates 
more quickly and at a lower price. Chief roles of computation in drug discovery are; Virtual 
screening, in silico ADME/T prediction & de novo design and advanced strategies for 
determining protein-ligand binding. 
 
1.4 In Silico target identification  
The in silico approach for novel drug target identification depends on genomic data. Genome 
information are helpful in the recognition, validation, choice of the potential candidates and 
screening based on "essentiality" and "selectivity" criteria of the microbial systems [10]. These 
subtractive genomics approach are used for choosing non homologous protein coding gene, 
found in pathogen but not in host. These genes are crucial for the existence of pathogenic 
bacteria and not present in human. This will cut back the chance of cross reactivity and side 
effects. In this case, Peptide Deformylase has been selected as a novel drug target on the basis of 
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essentiality and selectivity criteria. This protein is essential for bacterial survival, removes 
formyl group from nascent peptide and lead to protein maturation. There is no risk of cross 
reactivity because in human, equivalent functional PDF protein is not yet reported. 
The protein executes its function through interaction with other molecules such as ligand, 
substrate, DNA and other domains of proteins. The 3-D structure of protein provides the 
mandatory shape and physicochemical texture to facilitate these interactions. Structural data of 
protein surface regions enables detailed studies of the relationship of protein structure and 
function. The very first step to obtain a good result should be the identification and visualization 
of protein cavities for structure-based drug design (SBDD) applications. The activities of protein 
exist in the cavities where binding of substrate lead to triggering some incident, such as a 
conformational change or chemical modification. There are various server are present on internet 
that can be use for finding active site. CASTp, pocket finder, Q site finder, PASS are some 
available server used for identifying active site in our target PDF. 
            To identify a reliable and potent drug for protein target protein-ligand autodocking are 
used. The aim of docking is to predict the binding energy of the protein-ligand complex given 
the atomic coordinates. Recent enhancements in search algorithms and energy functions, 
computational docking strategies became a valuable tool to explore the interaction between 
protein and its inhibitors. The binding energy between the protein and its ligand is calculated by 
a simplified, often grid-based force field [11]. 
Active sites of a protein are key factor for the flexible docking. Autodock4.2 is an automated 
docking tool that predicts how ligand molecules bind to receptor of known 3D structure and it 
also optionally enables to model binding parameters of ligand with number of distinct 
conformational clusters and to find all possible minimum binding energy. 
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1.5 Objectives 
The primary objectives of current project are: 
1. To identify the different pathogenic bacteria’s expressing PDF protein and to perform 
multiple sequence alignment to find the similarity between PDF proteins. 
2. To identify a new class of molecule that has potential to inhibit PDF. 
3. To analyze the derivatives (from PubChem) of selected molecule for their potential to be 
broad spectrum antibacterial drugs. 
4. To analyze and dock all chosen molecules for the identification of novel drug candidates. 
5. To study molecular, ADME, toxicity properties and MD simulations of novel drug 
candidates. 
1.6 Plan of Work 
Plan of Work 3rd Semester 4th Semester 
      
  
Mid 
Semester 
End 
Semester 
Mid 
Semester 
End 
Semester 
  
Literature review 
  
  
Identification a new class of molecule that 
has potential to inhibit PDF     
  
Analysis of derivatives of identified 
molecule and docking with whole set of PDF       
  
Study of molecular, ADME, toxicity 
properties and MD simulations of novel drug 
candidates.     
  
Manuscript writing 
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2. LITERATURE REVIEW 
 
2.1 Function of peptide deformylase 
The prokaryotic and eukaryotic organelle (mitochondrial and chloroplast) ribosomal protein 
synthesis universally initiates with an N-formylmethionine residue[12]. Peptide Deformylase 
(PDF) is an essential metalloenzyme that removes the formyl group from methionine at the N 
terminus of nascent polypeptide chains followed by protein maturation. This protein is expressed 
in all pathogenic bateria, together with Mycoplasma and Chlamydia species. The bacterial PDF 
is encoded by “def gene”. functionally equivalent gene is not found within mammalian cells [13]. 
This “def gene” is a vital for bacterial growth and survival [14-15]. The catalytic domain of PDF 
contains three extremely conserved motifs and belongs to the matrix metallo-protease (MMP) 
family of enzymes. The PDF enzyme requires a single ferrous ion for its activity and catalyzing 
the reaction 
N-formyl-L-methionine + H2O = formate + methionyl peptide. 
In all prokaryotes, a formyl-methionine residue is inherently incorporated at the N-terminus of 
all nascent polypeptides; however, the vast majority of the N-formyl moiety is removed from the 
mature proteins. The removal of the N-formyl moiety is catalyzed by Peptide Deformylase 
(PDF) [16-17]. But, significantly only half of all the polypeptides retain the methionine at their 
N-terminus [18]. The removal of the N-terminal methionine residue from the nascent 
polypeptides is catalyzed by the action of methionine aminopeptidase (MAP) [18]. PDF plays, at 
least, a critical role in mediating the maturation process of the emerging polypeptides, partially 
due to the requirement of removing the N-formyl group to render the nascent polypeptides for 
MAP cleavage of the N-terminal methionine residue. Blockade of bacterial Peptide Deformylase 
produces inhibition to protein synthesis. In fact, the disruption of the PDF encoding gene in E. 
coli proved critical for cell survival [14, 19], making it an attractive drug target. 
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Figure 1:  Protein biosynthesis pathway in bacteria, mitochondria, and plastid. Met- methionine; 
AA- amino acids. 
 
2.2 Structure of Peptide Deformylase 
The three-dimensional structure of PDF has been determined for various bacterial species. 
Moreover, several enzyme–inhibitor complex structures were also resolved [20]. The structure of 
zinc-containing E. coli PDF (Ec-PDF) was at first solved by NMR methods and by X-ray 
crystallography [21-22]. The 3-D structure of PDF revealed that the metal ion (Fe
2+
) is 
tetrahedrally coordinated by Cys90, His132, His136 and a H2O molecule. Since Fe
2+
 is sensitive 
to oxygen so for ease of enzymatic study, the ferrous-containing PDF can be replaced by a 
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divalent metal such as Ni
2+
 [23] or Co
2+
 [24] to make a highly stable and fully active enzyme, as 
well as that enables spectroscopic studies. A worthy note here is that the enzyme, in both nickel-
containing and cobalt-containing PDF, is oxygen insensitive and catalytically as active as the 
ferrous-containing PDF. From S. aureus  the PDF have isolated (SaPDF) and its crystal structure  
was determined in complex with its natural inhibitor actinonin at 1.90 Å resolutions by Hye-Jin 
Yoon et al. [25]. The three-dimensional structures of the PDF with synthetic inhibitors disclose 
that the active-site metal ion is pentacoordinated by the metal-binding ligands of the inhibitors 
[26]. 
 
Figure 2: Crystal structures of PDF (A) E.coli Zn-PDF structure, (B) E.coli Zn-PDF-PCLNA 
complex 
 
2.3 Peptide Deformylase in Eukaryotes 
Protein synthesis in the cytoplasm of eukaryotes doesn’t begin with N-formylmethionine, and 
undoubtedly the need for deformylation in the cytoplasmic process is apparently deficient. 
However, PDF like homologs are revealed in eukaryotes. In addition to plants a number of 
plastid containing parasites such as Plasmodium falciparum shown to have nuclear encoded gene 
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homolog [27]. But from sequence alignment, P.falciparum PDF shows a 33% identity to the 
bacterial PDF, alongwith around 60 amino acid extensions at the N-terminus. This demonstrates 
that, the extra extension is a bipartite N-terminal pre-sequence that consists of signal peptide for 
entry into the secretary pathway and a plant-like transit peptide for subsequent import into the 
apicoplast of the Plasmodium. Moreover, PDF-like sequences have been recognized in the 
genomes of Drosophila Melanogaster, as well as in the partial expressed sequence tags (ESTs) of 
mouse and human [28]. Like PfPDF, all of these eukaryotic PDF sequences contain an extra ~60 
amino acid N-terminal extension. Finally in eukaryotes, these PDF-like gene sequences are not 
known to be expressed and, if expressed at all, to encode a functional PDF [12]. PDF exists in 
three forms: PDF1A, PDF1B and PDF2. PDF1B and PDF2 are found in bacteria only and 
PDF1A is found in human (mPDF) [29]. Therefore, inhibitors selective for bacterial Peptide 
Deformylase do not show inhibitory activity against mPDF. The bacterial Peptide Deformylase 
inhibitors (PDIs) are very selective and show activity against similar mammalian (including 
human) enzymes only at extremely high concentrations which not seems to be achievable in vivo 
[15]. This has shown by various studies. For instance, the Peptide Deformylase (Ni complex) of 
S. pneumoniae, Haemophilus influenzae, E. coli, and S. aureus was inhibited by BB-81384  with 
IC50 values of 9, 11, 60, and 300 nM, respectively [8] whereas equivalent IC50 values for the 
human metalloenzymes collagenase (MMP-1), gelatinase (MMP-2) and angiotensin converting 
enzyme (ACE) were found to be 10000, 60000, and 5000 nM, respectively [8] (corresponding 
IC50 refers to the concentration inhibiting enzyme activity by 50 percent). Moreover it was 
found that in the development of VRC 3852, 20 out of 21 related compounds (95%) showed 
IC50 values of 100 nM or less for E. coli PDF and 18 out 20 (90%) showed IC50 values of 75 
nM or less for S. pneumoniae peptide deformylase. But in the case of human, all 21 compounds 
were very selective for PDF, with IC50 values for tested human metalloenzymes being 200000 
nM or greater [9].  
 
2.4 Peptide Deformylase as Novel Drug Target 
Since PDF is required for bacterial survival but apparently unnecessary in animal cells, it 
provides an attractive target for a novel antibacterial strategy. Moreover, deformylation is a 
conserved feature throughout the eubacterial kingdom. With the numerous three-dimensional 
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structures of various bacterial PDFs solved [30-34], both with and without enzyme-bound 
inhibitor complexes, it appeared that the active site of PDF is conserved, composing of sequence 
motifs, motif 1 [GφGφAAXQ], motif 2 [EGCLS], and motif 3 [HEφDH] (where φis a 
hydrophobic amino acid and X is any amino acid) [26, 35]. Consequently, PDF appears to be a 
broad spectrum novel antibiotic drug target. 
One notable advance in PDF inhibitor screening came from the random screenings by Versicor 
and Hoffmann-La Roche [36-37]. The work led to the identification of actinonin, a naturally 
occurring hydroxamic acid derivative known to have potent antibacterial activity and it is a PDF 
target. In vitro activity of actinonin against PDF is within Ki value of 0.3 nM and demonstrated 
bacteriostatic activity against a wide spectrum of Gram-positive and Gram-negative bacteria. 
Evidence to support the molecular target for antibacterial activity of actinonin came from the E. 
coli genetic construct in which mutant E. coli strain expresses controllable levels of PDF [37]. 
Thus, the susceptibility to the presence of actinonin is associated with the different expressed 
levels of PDF within the bacterial cell (at high PDF expression level, the bacterial cell becomes 
more tolerable to the presence of actinonin) [37]. Despite having strong inhibition for PDF, 
actinonin was never developed for the treatment of infections due to its poor bioavailability and 
consequent lack of in vivo efficacy [38]. 
Peptide deformylase (PDF) inhibitors have long been sought as antimicrobial agents. The 
discovery of inhibition of PDF by actinonin oriented research efforts toward peptidomimetic, 
hydroxamic acid-based inhibitors. Hence, the general structure of most current PDF inhibitors 
contains a strong chelating moiety such as a hydroxamic acid. Owing to a structural lead from 
actinonin, BB-3497 was developed to target PDF (KI= 9 nM) with moderate antibacterial 
activity against a range of bacterial pathogens followed by oral administration [39]. N-alkyl urea 
hydroxamic acids were also shown have antibacterial activity against PDF [9]. Also results 
showed that hydrazides could give better results as an inhibitory drug against PDF [40]. 
Moreover the PDF is present in diverse group of eubacteria. This will allow the identification of 
broad spectrum antibiotics. The aim of this project is to identify more chemical compounds 
showing anti bacterial properties against PDF and to study their molecular, ADME, and toxicity 
properties along with pharmacophore modeling and Molecular Dynamics (MD) simulation of 
protein-ligand complex to analyze the stability under biological conditions. 
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2.5 Novel drug design strategy 
Drug discovery and development is highly complex and, lengthy and process. For a new ligand 
to reach in the market as a potent drug must develop by the process which is commonly known 
as developmental chain or “pipeline: and consists of a number of distinct stages [41]. Generally it 
can be grouped under two stages, early pharmaceutical research and late pharmaceutical R&D. 
Early pharmaceutical research involves two steps process in which identification and modeling 
of the biological target within the body (the protein) is the first step, followed by the second step 
of identification of lead compound (ligand) that shows drug-like properties with respect to this 
protein. Later, the drug goes through many phases of clinical development in humans. In the 
clinical stage, the drug is administered first to animals and then to human volunteers to 
determine: 
 The channel of the drug through the body- starting the time when it is administered in the 
body to the time when it is excreted from the body. 
 Drug’s effects on the body. 
 Its efficiency to cure the disease being treated. 
 Adverse side effects of the drug. 
 
Figure 3: Drug discovery and development process. 
However, failure of most candidate molecule can occur as a result of combination of reasons 
such as poor pharmacodynamics, poor pharmacokinetics, side effects, lack of efficacy and 
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commercial reasons. Also the cost and time required for the development of new drug from 
conventional method is very high. From conventional methods it would take approx $1.8 billion 
and 15 years from the initial stage to the successful marketing of a new drug [42]. Most drugs are 
discovered by either modifying the structure of known drugs, by screening compound libraries or 
by developing proteins as therapeutic agents [42]. With the advent of genomics, proteomics, 
bioinformatics and technologies like, NMR, crystallography, the structures of more and more 
protein targets are becoming available. So, there is an urge need for  novel computational tools 
for drug designing that can identify and analyze active sites and suggest potential drug molecule 
that can bind to these sites and not only shorten the R&D time cycle but also reduce the ever 
increasing cost involved in the drug discovery process. In silico drug design or CADD 
(Computer Aided Drug Design) method fills this research requirement. Moreover, 
PricewaterhouseCoopers states that “the overall cost of drug development could be reduce by as 
much as 50% through extensive use of in silico technologies in drug discovery procedure” [43]. 
Also, studies from quantum mechanics, molecular dynamics, molecular dockings, QSAR to 
ADMET prediction including dissolution studies are performed in silico.  
 
Figure 4:  Application of in silico drug design (CADD) in various stages of drug development. 
In silico drug discovery process comprise of three stages: 
(i) First stage involves identification of a therapeutic target and building a heterogeneous 
small molecule library to be tested against it, followed by the development of a 
virtual screening protocol initialized by either docking of small molecule from the 
library or building these structures in the active site by De novo design method.  
(ii) In second stage, these selected hits are checked for specificity by docking at binding 
sites of other known drug targets.  
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(iii) In third stage, these selected hits are subjected to detail in silico ADMET profiling 
studies and those molecules that pass these studies are termed as leads [44]. These 
lead molecules can be further carried through drug discovery and development cycle. 
 
2.6 Methods of virtual screening in drug design process 
The shift from conventional to genomics and proteomics based drug design research has 
fundamentally transformed key R&D strategies in the pharmaceutical industry addressed to the 
design of new chemical entities as drug candidates against a variety of biological targets. 
Therefore, drug discovery has encouraged toward more rational strategies based on our 
increasing understanding of the fundamental principles of protein-ligand interactions [45]. 
Virtual screening is generally referred to as the process of scoring and ranking molecules in large 
chemical libraries according to their state of having affinity for a definite target, [46].  
Mainly, there are two methods of virtual screening: ligand-based and target-based. Analysis and 
comparison of ligand-based virtual screening and target-based virtual screening imply that the 
knowledge about a target obtained from known bioactive ligands is as important as information 
of the target structures itself for identifying novel bioactive scaffolds through virtual screening 
[47-48]. Hence, the absolute selection for a method to use will finally depend on the type and 
amount of information available without prior having a large impact on performance. 
 
2.6.1 Ligand-based virtual screening 
There exist a broad range of ligand-based virtual screening methods. The extent of complexity, 
and thus the final computational cost of these methods, depends greatly on the type of structural 
information of ligand being used [49]. Each and every one  of these methods rely on the 
fundamental similarity-property principle according to which similar molecules should exhibit 
similar properties [50] and therefore chemical similarity calculations form the foundation of 
ligand-based virtual screening [51]. Thus, all the molecules in a particular database can be scored 
comparative to the similarity to one or multiple bioactive ligands and then ranked accordingly to 
reflect decreasing possibility of being active.  
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2.6.2 Target-based virtual screening 
The availability of structural information of the target protein, that being either determined 
experimentally or derived computationally by means of homology modeling techniques is the 
core of Target-based virtual screening methods [52-53]. The aim of these methods is to provide, 
on one side, a good approximation of the expected conformation and orientation of the ligand 
into the protein cavity (docking) and, on the other side, a reasonable estimation of its binding 
affinity (scoring). The goal is to select from existing compound libraries or to design compounds 
with three-dimensional complementarity (i.e. shape, size and physicochemical properties) to the 
target-binding site. Advancement and new approaches can directly guide the design of virtual 
combinatorial libraries, which are first tested in silico for target complementarity. This will 
reduce the number of compounds that have to be synthesized and tested in vitro. Target based 
virtual screening is most popular and gained a reputation in successfully identifying and 
generating novel bioactive compounds. 
 
2.6.3 Diversity based virtual screening 
The aim of diversity based virtual screening is to select a smaller sub-library from a larger 
compound library in such a way that the full range of chemical diversity is best represented [54]. 
When the structural information about the target or ligand or both is unavailable, diversity design 
is the method of choice. 
 
2.7 Docking of protein and drug molecules by AutoDock tool 
 AutoDock is widely used in the prediction of bimolecular complexes for structure & functional 
analysis and in molecular design. It combines an empirical free energy force field with a 
Lamarckian Genetic Algorithm (LGA), providing fast prediction of bound conformations with 
predicted free energies of association [55]. 
AutoDock was released in 1990 [56] and consistently from early time it has proven to be an 
effective tool. It can predict accurately and quickly the bound conformations and binding 
 18 
 
energies of ligand with macromolecular targets [55, 57]. The primary algorithm used by 
AutoDock for conformational searching is the Lamarckian Genetic Algorithm (LGA) [55]. The 
“Lamarckian” allows individual conformations to search their local conformational space, to find 
local minima, and ultimately pass this information to later generations. AutoDock4 is also 
incorporated with simulated annealing (SA) search method and a traditional genetic algorithm 
(GA) search method. It uses a semi empirical free energy force field to predict binding free 
energies of small molecules to macromolecular targets [57] and shows a standard error of about 
2–3 kcal/mol in prediction of binding free energy in cross-validation studies. 
AutoDock Tools (ADT) is inbuilt with object-oriented programming language Python which is 
made from reusable software components [58-59]. ADT exists in the context of a rich set of tools 
for molecular modeling, the Python Molecular Viewer (PMV) [59-60]. PMV is a freely 
distributed Python-based molecular viewer. ADT consist of a set of commands dynamically 
extending PMV with commands specific for the preparation, launching and analysis of 
AutoDock calculations. Hence all PMV commands are naturally available in AutoDock tools. 
 
2.8 Molecular dynamics simulation: a method for validation of docking result  
Molecular Dynamics (MD) simulation is a theoretical physics technique used for the analysis of 
molecular system at atomic level and has sound basis in statistical mechanics and classical 
physics [60-61]. MD simulation is a method for time scale generation of conformations, 
thermodynamic information, system total energy with kinetic and potential energy of proteins 
and other biological macromolecules [62-64]. MD simulation provides fine detail concerning the 
motions of individual particles as a function of time and can be utilized for the quantification of 
properties of a system at a precision and on a time scale that is otherwise difficult to get to. 
Therefore, in extending our knowledge of model systems simulation plays as a valuable tool. An 
important aspect of MD simulation is that theoretical consideration of a system additionally 
allows one to investigate the specific contributions to a property through “computational 
alchemy” [65] i.e., modifying the simulation in a way that is nonphysical but nonetheless allows 
a model’s characteristics to be probed. The artificial conversion of the energy functions from that 
representing one system to that of another during a simulation represents an example of 
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computational alchemy. This technique is important and use for free-energy calculations [66]. 
Hence, MD simulation with its range of complementary computational advancement, has proven 
to be a valuable tool for exploring the basis of protein structure and function [67]. 
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3. MATERIALS AND METHODS 
 
3.1 Bioinformatics softwares and tools used 
1. NCBI 
2. Clustal Omega 
3. BLAST  
4. Protein Data Bank (PDB) 
5. CASTp 
6. PubChem 
7. ArgusLab 
8. Molsoft 
9. PreADMET 
10. PRODRG2 
11. AutoDock4.2 
12. Open babel 2.3.1  
13. LigPlot+ 
14. UCSF Chimera 
15. Rasmol 
16. PyMOL 
17. LigandScout3.1 
18. GROMACS4.05 
19.  Marvin Space 
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3.2 Flow chart of protocol followed 
 
Data Base Search and target identification 
 
Rretrieval of amino acid sequences of PDF enzyme of selected bacteria’s from NCBI 
 
Multiple sequence alignment of retrieved PDF protein sequences using Clustal Omega 
 
Target validation using BLAST 
 
Retrieving 3-D Model of the protein from PDB 
 
Active Site Identification using CASTp 
 
Target geometry cleaning and optimization using ArgusLab 
 
Identification of ligands from pubchem 
 
Molecular properties and drug likeness calculation of ligands using Molsoft 
 
ADME properties and toxicity testing of ligands using PreADMET server 
 
Energy minimization of all  ligand structures by PRODRG server 
 
Docking of target and ligand by AutoDock4.2 
 
Hydrogen bond analysis of docked complex by Ligplot+ for 2D and UCSF Chimera for 3D 
 
Pharmacophore modeling of best docked complex by LigandScout3.1 
 
Molecular dynamics simulation studies of best docked complex by GROMACS4.05 
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3.3 Data Base Search and target identification 
After literature survey the database search was carried out to find microorganism expressing 
PDF protein. The protein data bank is the repository for 3-D structural data of large biological 
molecules, such as nucleic acids and proteins. These structural data are usually obtained by X-
Ray Crystallography and NMR spectroscopy. From the protein data bank 35 different bacteria 
expressing PDF protein were found. In these we select following threaten pathogenic bacteria for 
further study- 
 Leptospira interrogans 
 E.coli 
 Enterococcus faecium 
 Pseudomonas aeruginosa 
 Vibrio cholerae 
 Staphylococcus aureus 
 Streptococcus pneumoiae. 
 
3.4 Retrieval of amino acid sequences of PDF enzyme of selected bacteria’s from NCBI    
National Centre for Biotechnology Information (NCBI) was established on Nov 4, 1988 as a 
division of the National Library of Medicine (NLM) at the National Institutes of Health (NIH). It 
provides an inclusive website that features biological databases and tools for viewing and 
analyzing the information inherent within the databases. It allows researchers, biologist to access 
and retrieve biological information from the website. NCBI constructs automatic systems for 
storing and analyzing information regarding biology, organic chemistry, and genetics; facilitating 
the employment of such databases and software system by the research and medical community; 
coordinating efforts to collect biotechnology information each nationwide and internationally; 
and performing research into advanced strategies of computer-based informatics for analyzing 
the structure and performance of biologically necessary molecules. 
 The URL http://www.ncbi.nlm.nih.gov was open. 
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 In the search option “Protein” was selected and name of protein & bacteria was written 
for retrieving amino acid sequence.  
 The sequence format was set to FASTA. 
 The amino acid sequences of PDF for each bacterium were retrieved and saved.  
 
Figure 5: Screenshot of FASTA format of Peptide Deformylase (E.Coli) on NCBI web page. 
 
3.5 Multiple sequence alignment of retrieved PDF protein sequences using Clustal Omega 
Clustal Omega is a tool developed and maintain by European Bioinformatics Institute (EBI). It 
produces biologically significant multiple sequence alignments (MSA) and calculates the most 
effective match for selected sequences and features them up, thus identities, similarities and 
variations can be identified. 
Multiple sequence alignment of PDF protein from the entire selected organism was performed in 
order to calculate the percentage identity between them. The tool Clustal Omega used for this 
purpose was available on internet.  
 The URL http://www.ebi.ac.uk/Tools/msa/clustalo was opened. 
 The FASTA format of all retrieved PDF protein sequences was prepared in notepad. 
 In step 1 the set of protein sequences were paste in “enter input sequences” option bar. 
 The default parameters were set in step 2. 
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 The job was submitted in step 3. 
 
Figure 6: Screenshot of multiple sequence alignment tool Clustal Omega. 
 
3.6 Target validation using BLAST 
PDF enzyme is encoded by the def gene, and is present in all disease causing bacteria. 
Functionally equivalent gene is not present in mammalian cells. Therefore, the target protein is 
valid. 
Moreover for the confirmation of absence of functionally equivalent gene of PDF in human, 
protein BLAST was run. It stands for Basic Local Alignment Search Tool. It is an algorithm that 
compares primary biological sequences such as protein and DNA and is provided by NCBI. 
 The URL http://www.ncbi.nlm.nih.gov was accessed to open the NCBI homepage.  
 BLAST option was clicked. 
 For comparing protein sequences pBLAST was selected.  
 In the “query sequence” search option FASTA format of bacterial PDF was entered. 
 In “choose search set” option database was set to non redundant protein sequences and 
organism was set to Homo sapiens (taxid: 9606). 
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 Algorithm was set to blastp (protein-protein BLAST). 
 Program was run and the result was saved. 
 
Figure 7: Screenshot of BLAST homepage. 
 
3.7 Retrieving 3-D Model of the protein from PDB: 
After validating the target protein its 3-D structure have been downloaded and studied. The 3-D 
structure of the protein was obtained in pdb format from protein primary database structure PDB.  
 The URL http://www.rcsb.org/pdb/home/home.do was opened. 
 The four letter pdb code of protein was entered in the search option. 
 Files were downloaded in pdb format and saved. 
 27 
 
 
Figure 8: Screenshot of Protein Database (PDB) webpage. 
We download the respective pdb file of Peptide Deformylase (PDF) of selected bacterium. The 
name of microorganisms, their respective PDF PDB Id and download link is listed below- 
Table 1: List of microorganism and their respective PDF PDB Id and download link 
S.No
. 
PDB 
ID  
Organism Protein Reference 
          
1 1N5N Pseudomonas 
aeruginosa 
Peptide 
Deformylase 
http://www.rcsb.org/pdb/explore/explore.do?stru
ctureId=1N5N 
2 1BSK Esherichia coli Peptide 
Deformylase 
http://www.rcsb.org/pdb/explore/explore.do?stru
ctureId=1BSK 
3 3G6N Enterococcus 
faecium 
Peptide 
Deformylase 
http://www.rcsb.org/pdb/explore/explore.do?stru
ctureId=3G6N 
4 1SZZ Leptospira 
interrogans 
Peptide 
Deformylase 
http://www.rcsb.org/pdb/explore/explore.do?stru
ctureId=1SZZ 
5 3L87 Sreptococcus 
mutans 
Peptide 
Deformylase 
http://www.rcsb.org/pdb/explore/explore.do?stru
ctureId=3L87 
6 3QU1 Vibrio cholerae Peptide 
Deformylase 
http://www.rcsb.org/pdb/explore/explore.do?stru
ctureId=3QU1 
7 1LQW Staphylococcus 
aureus 
Peptide 
Deformylase 
http://www.rcsb.org/pdb/explore/explore.do?stru
ctureId=1LQW 
8 1XEN Esherichia coli Peptide 
Deformylase 
http://www.rcsb.org/pdb/explore/explore.do?stru
ctureId=1XEN 
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3.8 Active Site Identification using CASTp 
Sites of activity in proteins usually lie in cavities. It is the size and shape of protein cavities that 
dictates the three-dimensional geometry of ligand so as to fit likes a hand in glove. The binding 
of a substrate typically serves as a mechanism for chemical modification or conformational 
change of protein. Binding sites are often targeted by various ligands in attempts to interrupt 
related molecular processes. Active sites of a protein are a key factor for the flexible docking. 
Active sites of the Peptide Deformylase (PDF) were predicted by using tool CASTp (computed 
atlas of surface topography of proteins). CASTp calculates concave surface regions on three-
dimensional structures of proteins. For this it takes into account of pockets located on protein 
surfaces and voids buried in the interior of proteins that are frequently associated with binding 
events. Also, it calculates the size of mouth openings of individual pockets for better 
accessibility of binding sites to various ligands and substrates. The result obtained made more 
precise by pocket Finder and Q site Finder. 
 
Figure 9: Screenshot of CASTp server interpreting active site of PDF protein. 
For more precise docking studies information about active metal binding amino acid residue was 
obtained from UniProt. The URL of this site is http://www.uniprot.org/uniprot/ 
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Figure 10: Screenshot of UniProt showing active metal binding amino acid residue. 
 
3.9 Target geometry cleaning and optimization using ArgusLab: 
The target obtain from above step is validated in software’s where it is converted from higher energy and 
less stable state to lower energy and more stable state. ArgusLab is a molecular modeling, graphics and 
drug design software freely available for windows operating system. 
 The chosen macromolecule was opened with the help of ArgusLab. 
 Water molecules were deleted. 
 If extra peptide chain present it was deleted.  
 Except the metallic ion other hetero and miscellaneous residues were deleted. Metallic ion was 
not deleted because it is important for catalytic activity of enzyme.  
 Clean the geometry by clicking the clean button on the toolbar the structure of the molecule 
changes as its geometry is cleaned. This step is followed as long as the macromolecules geometry 
is not cleaned. 
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Figure 11: Screenshot of ArgusLab molecular modeling tool showing geometry cleaning of PDF. 
 
3.10 Identification of ligands from PubChem 
After going several literature surveys, we found that the molecules which have potential as an 
antibacterial drug by inhibiting PDF protein were hydroxamic acid derivatives. Actinonin and 
macrolactin N are the only naturally-occurring PDIs (Peptide Deformylase inhibitors) [37, 68]. 
Actinonin form the framework for the synthesis, purification, and estimation of more potent 
PDIs (s), so we choose actinonin as our reference drug. It has already been shows that the 
hydrazides have a potential to inhibit the PDF’s [40]. Taking it in consideration and making our 
work novel, we proceeded our studied with hydrazine, a related class of hydrazides. We targeted 
important members of this class called sulfonylhydrazides to study their ability to inhibit Protein 
Deformylase. The 3D chemical structure of ligands was obtained from PubChem. It is a database 
which offers information about the biological activities of small molecules and includes 
substance information, compound structure, bioactivity data, origin and related literatures. 
Ligand optimization and minimization was done using Argus Lab software. After analyzing their 
binding energies using Autodock4.2 software we found that compound sulfonylpiperidine gave 
very good result compared to actinonin. After then eliminating all other molecules we concise 
our study by focusing on sulfonylpiperidine and searched all derivatives available on PubChem. 
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We select different derivatives of Sulfonylpiperdine for further study. To get different isomers of 
sulfonylpipridine first we visited PubChem database webpage; enter “sulfonylpiperidine” in 
search bar. Selecting the first member of this family we went to structure search tool and search 
similar compounds with similarity score greater than 90%. It searches 118 different derivatives 
of sulfonylpiperidine. We accessed PubChem on 21st August, 2012. 
 
3.11 Molecular properties and drug likeness calculation of ligands using Molsoft  
Molsoft is web-enabled Cheminformatics system that provides wide range of software tools 
supporting molecule manipulation and processing, plus SMILES and SD file conversion, 
standardization of molecules, generation of tautomers, molecule fragmentation, calculation of 
various molecular properties required in QSAR, molecular modeling and drug design, high 
quality molecule depiction, molecular database tools supporting substructure and similarity  
searches, also  hold  fragment-based virtual screening, bioactivity prediction and data 
visualization. 
 The URL http://molsoft.com/mprop/ was accessed to open Molsoft server.  
 In “Enter SMILES” option bar the SMILES format of ligand was paste and software was 
run to calculate properties and to predict bioactivity. 
 
Figure 12: Screenshot of Molsoft molecular properties prediction tool. 
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3.12 ADME properties and toxicity testing of ligands using PreADMET server 
An important tailback remains in the drug discovery process, particular in the later stages of lead 
discovery, is analysis of the ADME and obvious toxicity properties of drug candidates. More 
than 50% of the drug candidates failed because of ADME/Toxicity deficiencies during drug 
development process. So in most pharmaceutical corporations a collection of in vitro 
ADME/Tox screens has been enforced to avoid this failure at the development of novel drug 
with the aim of discarding compounds within the discovery section that are seemingly to fail any 
down the line. PreADMET is a web based application which speedily predicts the drug-likeness 
and ADME/Tox knowledge of drug candidates. 
 The URL http://preadmet.bmdrc.org/ was accessed to open PreADMET. 
 Chemical structure of ligand was drew and submitted. The result was saved carefully. 
. 
Figure 13: Screenshot of PreADMET tool used for ADME/Tox property prediction.  
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3.13 Energy minimization of all ligand structures by PRODRG server 
PRODRG is an online server that takes an account of small molecules as PDB coordinates, MDL 
molfile/ sdf file/ SYBYL Moll2 file/ text drawing and from it produce a variety of topologies for 
use with Autodock, GROMACS, REFMAC, SHELX, WHAT IF, HEX, CNS, O and other 
programs, as well as energy minimized coordinates in a range of formats. 
 The URL http://davapc1.bioch.dundee.ac.uk/prodrg/ was accessed to open PRODRG 
server. 
 The token was get by giving email id. 
 PubChem was opened, ligand id was entered, sdf file format of ligand was copied and 
pasted in PRODRG server. The chirality was set to “yes”, charges to “full” and energy 
minimization to “yes”. 
 Run PRODRG and “pdb (polar hydrogens)” of minimized ligand was saved in pdb 
format. 
 
Figure 14: Screenshot of PRODRG energy minimization server. 
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3.14 Docking of target and ligand by AutoDock4.2 - 
AutoDock4.2 is a set of automated tools and is freely available under the GNU General Public 
License. It is designed to predict how small molecules, like substrates or drug molecules, bind to 
a receptor ok known 3D structure. Two programs on which AutoDock is based are, autodock 
program that performs the docking of the ligand to set of grids describing the target protein and 
the autogrid program that pre calculates these grids. Autodock program employed Lamarckian 
Genetic Algorithm to explore low binding energy orientations. It is faster than earlier versions 
and has AMBER force field, free energy scoring function that is based on a regression analysis 
and a larger set of diverse protein-ligand complexes with known inhibition constants. 
AutoDock4.2 used autogrid program to produce grid maps. The spacing between the grids was 
set default value of 0.375 A
o
. The centre of grid was set to active metal binding amino acid 
residue and grid dimensions were set to 60 × 60 × 60 A
o3
. The standard docking protocol was 
followed for flexible ligand docking and consisted of 10 independent GA runs for each ligand, 
using an initial randomly generated population of 150 binding orientations, with 2500000 energy 
evaluations, maximum number of 27000 generations, gene mutation rate of 0.02 and cross over 
rate of 0.80. The docked confirmation obtained was further clustered together with accepted 
RMSD of 0.5 A
o
.  The clusters were ranked by the lowest energy conformation of each cluster. 
Total 118 ligand molecules were docked against 8 bacterial Peptide Deformylase (PDF) proteins. 
 
Figure 15:  Showing docking of PDF (PDB Id-1N5N) with CID_4539974 
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3.15 Hydrogen bond analysis of docked complex by Ligplot+ for 2-D and UCSF Chimera 
for 3-D  
LigPlot+ is a freely available, user friendly program that automatically generates schematic 
diagram of the interaction between protein and ligand for a given PDB file of docked protein-
ligand complex and shows these interactions through hydrogen bonds and hydrophobic contacts. 
The H-bonds are represented by dashed lines between the atoms of ligand and protein, whereas, 
hydrophobic contacts are indicated by a convex arc, facing towards the ligand and radiating 
spikes. The contacted atoms are represented by concave arc towards each other and spoke 
radiating back. 
UCSF Chimera is a freely available on web and is highly extensible program. It is used for 
visualization and analysis of molecular structures and related data, including docking results, 
trajectories, conformational ensembles, density maps, sequence alignment and supramolecular 
assemblies. It generates images and animation of structures. 
We analyzed the docked structures with these two softwares. LigPlot+ is used for 2-D 
visualization and UCSF Chimera for 3-D visualization of Hydrogen bonds formed between 
protein and ligand molecule. UCSF Chimera represents the H-bond by blue and orange lines. 
 
3.16 Pharmacophore modeling of best docked complex by LigandScout3.1 
Pharmacophore models representing ligand-receptor interaction are derived from interaction of 
each molecule of ligand with its surrounding amino acid residues [69] and represents collection 
of molecular features which are necessary for molecular recognition and interaction of ligand by 
a protein. Pharmacophore modelling is playing a key role in the identification of ligand features 
for the particular targets [70-71]. 
We have done pharmacophore modeling using LigandScout3.1 software. It takes docked protein-
ligand complex and identifies the key features on the ligand. That features help the ligand to 
interact with points on the protein. 
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3.17 Molecular dynamics simulation studies of best docked complex by GROMACS4.05 
For MD simulation GROMACS (GROningen Machine for Chemical Simulations) software was 
used. It is a freely available and open source molecular dynamics simulation package. It is 
extremely fast and mainly designed for simulations of biochemical molecules like proteins, lipids 
and nucleic acids. It is operated via command-line and use files for input and output. 
 
Figure 16: Showing the basic molecular dynamics simulation strategy by Gromacs tool 
The molecular dynamics simulation was performed with GROMACS version 4.05 software 
packages for the molecules giving best docking and H-bond analysis result. The forcefield 
applied was GROMOS4031. The initial structure of protein was placed in a cubic box and filled 
with water. The energy minimization of the system was performed without restraint using 
steepest descent method for 100 steps. Then molecular dynamics equilibration was run at 300 K, 
with decreasing harmonic position restraints on the protein atoms over a 20 ps time interval, 
followed by 1 ns of MD equilibration without restraints. The P-LINCS algorithm was used for 
MD simulation. A dielectric constant of 1 and a time step of 2 fs were used. The temperature and 
pressure was kept constant during the MD simulations. 
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4. RESULT AND DISCUSSION 
 
4.1 Result of Multiple Sequence Alignment 
The multiple sequence alignment by Clustal Omega showed that the active site of PDF is 
conserved throughout the microorganisms, composing of  three sequence motifs, motif 1 
[GφGLAAXQ], motif 2 [EGCLS], and motif 3 [QHEφDH] (where φis a hydrophobic amino acid 
and X is any amino acid) (where φis a hydrophobic amino acid and X is any amino acid). 
Therefore, PDF appears to be a broad spectrum novel antibacterial drug target. 
 
Figure 17: Clustal Omega Multiple Sequence Alignment analysis of bacterial PDF protein 
                 sequences.  
 
4.2 BLAST output 
The BLAST of bacterial Peptide Deformylase protein sequence against non redundant protein 
sequences of Homo sapiens (taxid: 9606) by pBLAST program showed similarity below 40% 
and confirmed the absence of equivalent functional PDF protein in human. The essentiality of 
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PDF protein for bacterial protein synthesis along with conserved active site region in bacterial 
population and the absence of functionally equivalent protein in human fulfil the"essentiality" 
and "selectivity" criteria for choosing PDF as a novel drug target. 
 
Figure 18: BLAST analysis of bacterial PDF protein sequence against non redundant human 
                  protein sequences. 
 
4.3 Active site prediction 
Active sites of the target PDF protein of all organisms were predicted by CASTp, active site 
prediction tool. CASTp computation is based on the pocket algorithm of the alfa shape theory. 
The active site of protein with structural pockets and cavities were calculated for all bacteria’s. 
The result is shown below: 
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Table 2: CASTp calculation on active site residues. 
S.No. 
Protein 
Model 
Active Site Residues 
  
1 1BSK 
Val5, His7, Glu41, Glu42,Gly43, Ile44, Gly45, Leu46, Gln50, Ile86, Glu 87, Glu88, 
Gly89, Cys90, Leu91, Ile93, Pro94, Glu95, Gln96, Arg97, Leu125, Ile128, Cys129, 
His132, Glu133, His136, Leu161, Asp162, Lys165 
2 1LQW 
Ile77, Pro78, Asp80, Ser82, Gly83, Lys84, Tyr86, Tyr88, Cys111, Arg127, Ile128, 
Gln141, Leu142, Arg143, Leu144, Lys145, Gly146, Tyr147, Pro148, 
3 1N5N 
Met39, Tyr40, Pro43, Gly44, Ile45, Gly46, Gln51, Asp62, Ser64, Glu65, Lys67, Tyr88, 
Gln89, Glu90, Gly91, Cys92, Leu93, Val95, Pro96, Gly97, Phe98, Tyr99, Leu127, 
Val130, Cys131, His134, Glu135, His138 
4 1XEN 
Glu41, Glu42, Gly43, Ile44, Gly45, Gln50, Ile86, Glu87, Glu88, Gly89, Cys90, Leu91, 
Ile93, Pro94, Glu95, Gln96, Arg97, Leu125, Ile128, Cys129, His132, Glu133, His136 
5 3G6N 
Arg56, Gly57, Gly58, Val59, Gly60, Gln65, Leu108, Glu112, Gly113, Cys114, Leu115, 
Tyr150, Ile153, Val154, His157, Glu158, His161 
6 3L87 
Arg68, Gly70, Val71, Gly72, Leu73, Gln77, Leu125,  Glu129, Gly130, Leu132, 
Ser133, Val134, Arg136, Arg144, Tyr167, Ile170, Val171, His174, Glu175, Asp177, 
His178, Ile182, Met183, Phe184,  
7 3QU1 
Met1, Ala2, Val3, Leu4, Glu5, Ile6, Leu7, Thr8, Thr37, Leu38, Tyr39, Ala40, Thr41, 
Asp42, Asn43, Gly44, Ile45, Asp62, Leu63, Ser64, Aso65, Asn66, Arg67, Gly90, 
Cys91, Leu92, Val94, Pro95, Asp96, Tyr97, Tyr98, Phe126,  His162, Val163, Arg166, 
Arg168 
8 1SZZ 
Glu45, Gly46, Val47, Gly48, Gln53, Tyr71, Thr74, Phe97, Trp98, Glu99, Gly100, 
Cys101, Leu102, Val104, Pro105, Gly106, Met107, Arg108, Tyr136, Ile139, Val140, 
His143, Glu144, Asn166 
 
Furthermore, amino acid residues that involved in bonding with metal residue of protein i.e. 
active amino acid residues were obtained from UniProt server. 
 
Table 3: UniProt analysis of active metal binding amino acid residues. 
PDB id 1N5N 1BSK 3G6N 1SZZ 3L87 3QU1 1LQW 1XEN 
UniProt Active 
amino acid 
residue 
Cys92 Cys90 Cys114 Cys101 Cys131 Cys91 Cys111 Cys90 
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4.4 Docking result 
The docking of protein with ligand molecules was done step by step according to the standard 
procedure. It was done by automated docking tool AutoDock4.2. In order to find the novel drug 
against PDF first we docked the PDF enzyme of all selected bacteria with reference molecule. 
The reference molecule was selected Actinonin (CID_443600) which is a natural PDI (Peptide 
Deformylase Inhibitor). For most of the ligands, docking explicitly generated the 
crystallographic binding orientation within the protein cavity. For each ligand, 10 independent 
docking run were initiated with randomized populations and docking results for individual run 
were clustered if their final docked positions were within a tolerance of 0.5 A
0
. 
The docking result of PDF enzymes of selected bacteria with reference molecule actinonin is 
listed below: 
 
Table 4: Docking results of PDF with actinonin (CID_443600) 
S.No. Organism PDB iD 
Binding energy         
(-kcal/mol) 
Ki value 
(µmol) 
1 
Pseudomonas 
aeruginosa 
1N5N 7.66 2.44 
2 Esherichia coli 1BSK 7.23 4.99 
3 
Enterococcus 
faecium 
3G6N 6.61 13.1 
4 
Leptospira 
interrogans 
1SZZ 7.38 9.35 
5 
Sreptococcus 
mutans 
3L87 6.01 39.24 
6 Vibrio cholerae 3QU1 7.55 2.93 
7 
Staphylococcus 
aureus 
1LQW 6.96 7.85 
8 Esherichia coli 1XEN 7.07 6.57 
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Here we see that the highest binding affinity of actinonin is -7.66 kcal/mol with inhibition 
constant of 2.44 µmol. Actinonin gave this best result with PDF of Pseudomonas aeruginosa 
(1N5N). 
The top five best docking results of different derivatives of sulfonylpiperidine with PDF of all 
selected microorganism is given below: 
 
Table 5: Top five best docking results of isomers of sulfonylpiperidine with PDF 
S.No Organism PDB Id Compound Id Binding 
energy            
(-kcal/mol) 
Ki 
(nmol) 
  
1 Pseudomonas 
aeruginosa 
1N5N CID_3642762** 9.98 48.3 
CID_6391521 9.77 68.76 
CID_4025857 9.53 102.57 
CID_4538988 9.45 117.41 
CID_4539974* 9.24 167.54 
  
2 Esherichia coli 1BSK CID_4539974* 10.54 18.74 
CID_4025857 9.65 84.57 
CID_2761095 9.38 132.81 
CID_3642762** 9.28 157.64 
CID_2761072 9.11 209.1 
  
3 Enterococcus 
faecium 
3G6N CID_4539974* 9.67 81.02 
CID_3642860 9.2 181.44 
CID_3314532 8.87 314.55 
CID_4268983** 8.82 340.78 
CID_3642762** 8.75 385.56 
  
4 Leptospira 
interrogans 
1SZZ CID_4539974* 9.68 80.65 
CID_3642860 9.3 152.77 
CID_4268983** 9.02 244.85 
CID_3642762** 8.76 377.45 
CID_581405 8.64 464.43 
  
5 Sreptococcus 
mutans 
3L87 CID_3314532 9.04 234.99 
CID_300664 8.76 376.04 
CID_4539974* 8.75 383.02 
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CID_2886671 8.72 406.42 
CID_4268983** 8.61 485.42 
  
6 Vibrio cholerae 3QU1 CID_6391521 10.42 23.13 
CID_3642762** 10.31 27.92 
CID_5068042 10.25 30.59 
CID_4539974* 9.91 54.11 
CID_4268983** 9.8 65.61 
  
7 Staphylococcus 
aureus 
1LQW CID_3314532 10.36 25.42 
CID_4539974* 9.79 66.22 
CID_3642860 9.48 112.56 
CID_4268983** 9.16 191.76 
CID_5068042 9.14 199.53 
  
8 Esherichia coli 1XEN CID_4025857 9.79 67.06 
CID_4539974* 9.71 76.87 
CID_3642860 9.48 112.29 
CID_3642762** 9.35 139.85 
CID_4268983** 9.09 216.83 
 
From all docking results we sort out top five docking result for each bacterial PDF-
sulfonylpiperidine complex and represent in tabulated form above. We have sorted this result 
according to decreasing order of binding energy. Comparing from actinonin,  we find that even 
the highest binding energy of sulfonylpiperidine -8.61 kcal/mol (CID_4268983- 3L87 complex) 
is lower than the lowest binding energy of actinonin -7.66 (CID_443600- 1N5N complex). This 
result concluded that the sulfonylpiperidine has better inhibition capability for PDF than 
actinonin. Moreover we see that, the molecule CID_4539974 (shown with *) is present in top 
five best docking result of all microorganism. Molecules CID_3642762 and CID_4268983 
(shown with **) are present in top five best docking result of six microorganism. Based on this 
we filtered our result by selecting these three molecules CID_4539974, CID_4268983 and 
CID_3642762 for further analysis, narrowing our path with aim to get a novel potent Peptide 
Deformylase Inhibitor (PDI). 
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4.5 Hydrogen bond analysis of best docked molecules 
The residues involved in hydrogen bonding with drug candidate were analysed. LigPlot+ was 
used for 2-D and UCSF Chimera for 3-D analysis and confirmation of LigPlot+ results. The 
analysis was done for top 3 best docked structures. The result is shown below: 
 
Table 6: Amino acid residues to which ligand made H-bond and number of H-bonds made. 
S.No Organism PDB Id Active 
AA 
residue 
Compound 
Id 
No. of 
H-
bonds 
Hydrogen bonds with amino acid 
residue 
  
1 P.aeruginosa 1N5N Cys92 CID_4539974 6 Gly46,Tyr88,Gly91,Cys92, Cys 131, 
His134   
CID_3642762 3 Cys92, Leu93, Gly97 
CID_4268983 1 Gly97 
  
2 E.coli 1BSK Cys90 CID_4539974 8 Gly45, Gln50 (2), Gly89, Cys90, Leu91,      
Glu 133 (2) 
CID_3642762 3 Ile44, Gln50, Glu133 
CID_4268983 4 Gly45, Gln50, Glu95, Glu 133 
  
3 E.faecium 3G6N Cys114 CID_4539974 6 Gly60, Gln65, Gly 113, Tyr150, Glu 158 
(2) 
CID_3642762 4 Gln65, Gly113, Leu115, Tyr150 
CID_4268983 2 Gly113, Val154 
  
4 L.interrogans 1SZZ Cys 101 CID_4539974 5 Gln53 (2), Cys101, Leu102, His143 
CID_3642762 5 Gln53,Gly100, Cys101 (2), Leu102  
CID_4268983 7 Val47,Gly48, Gln53 (2),Tyr71, Cys101, 
Leu102  
  
5 S.mutans 3L87 Cys131 
Leu132 
CID_4539974 4 Gln77, Leu132, Glu177 (2) 
CID_3642762 4 Gln77, Leu132, Gly130 (2) 
CID_4268983 4 Val71, Gln77,Leu 132, Glu175 
  
6 V.cholerae 3QU1 Cys91 CID_4539974 6 Gly46, Gln51, Gly90, Cys91, Glu134, 
His137 
CID_3642762 5 Ile45, Gly46, Cys91, Leu92, Asp96  
CID_4268983 4 Leu92, Gln88, Glu134, His137 
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7 S.aureus 1LQW Cys111 CID_4539974 4 Gln65, Cys111, Leu112, His158 
CID_3642762 3 Gln65, Gly110, Leu114 
CID_4268983 4 Gln65, Gly110, Leu112, Glu155 
  
8 E.coli 1XEN Cys90 CID_4539974 3 Cys90, Leu91, Glu133 
CID_3642762 5 Ile44, Gly45, Cys90, Leu91, Glu95 
CID_4268983 4 Leu91, Arg97, Glu133, His136 
 
The pictorial representation of of best docked molecule is in figure 19. In the LigPlot+ analysis 
the dotted line shows the hydrogen bonding between the amino acid residues of protein and drug 
candidate. The violet coloured molecule is drug candidate. In the UCSF Chimera analysis the 
blue and orange coloured line shows hydrogen bonding and the fluorescent molecule is the drug 
candidate. The analysis of next two docked molecule were done in the same way and result 
shown in above table. 
 
  
1BSK-CID_4539974 ligplot analysis 1BSK-CID_4539974 UCSF chimera analysis 
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3G6N-CID_4539974 ligplot analysis 3G6N-CID_4539974 UCSF chimera analysis 
 
  
3QU1-CID_4539974 ligplot analysis 3QU1-CID_4539974 UCSF chimera analysis 
 
  
1N5N-CID_4539974 ligplot analysis 1N5N-CID_4539974 UCSF chimera analysis 
 47 
 
  
1SZZ-CID_4539974 ligplot analysis 1SZZ-CID_4539974 UCSF chimera analysis 
 
  
1LQW-CID_4539974 ligplot analysis 1LQW-CID_4539974 UCSF chimera analysis 
 
  
3L87-CID_4539974 ligplot analysis 3L87-CID_4539974 UCSF chimera analysis 
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1XEN-CID_4539974 ligplot analysis 1XEN-CID_4539974 UCSF chimera analysis 
 
Figure 19: Hydrogen bond analysis of CID_4539974 by LigPlot+ and UCSF Chimera  
 
The results of table show hydrogen bonding between drug candidate and amino acid residues of 
target protein. Furthermore, from the UniProt we identified the active amino acid residue for 
each protein that is bonded with metal residue. The active metal binding amino acid residue is 
crucial for the function of protein. This residue directly participates in catalysis and if we hinder 
this residue to make bond with metal ion, the biological functioning of protein is totally busted. 
This will add plus point to docking result. The position of active metal binding residue in the 
protein sequence is also shown in the table. From the result we see that the molecule 1-[(4-
methoxyphenyl)sulfonyl]piperidine-4-carbohydrazide (CID_4268983) makes hydrogen bond 
with active metal binding amino acid residue of 1SZZ and 3L87, molecule 1-[3-(tetrazol-1-
yl)phenyl]sulfonylpiperidine (CID_3642762) makes H-bond with active metal binding amino 
acid residue of 1N5N, 1SZZ, 3L87 and 1XEN and molecule 1-(4-
fluorophenyl)sulfonylpiperidine-3-carbohydrazide (CID_4539974) makes H-bond with active 
metal binding amino acid residue of almost all protein except 3G6N. In case of 3L87, the 
crystallized protein missed of Cys131 residue, so we consider its neighbor residue Leu132 as 
centre molecule. 
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4.6 Molecular, ADME properties calculation and toxicity testing result: 
The molecular properties calculation of 3 best docked molecules was done by molsoft online 
server, the ADME properties calculation and the toxicity testing was done by PreADMET server. 
The Molsoft calculates the molecular weight, number of hydrogen bond donor, number of 
hydrogen bond acceptor, octanol-water partition coefficient (LogP), and solubility (LogS). The 
PreADMET calculates the absorption, distribution, metabolism, excretion and toxicity properties 
of drug candidates. The drug-likeness model score for CID_4539974, CID_3642762 and 
CID_4268983 are 0.46, -0.64 and 0.58 respectively. 
   
CID_4539974 CID_3642762 CID_42689838 
Figure 20: Drug-likeness model score by Molsoft server. 
The result of Molsoft and PreADMET analysis of best 3 molecules are shown in tabulated form 
below: 
Table 7: Molsoft and PreADMET analysis of CID_4539974 
 
                 Molecular properties ADME properties Toxicity testing 
          Ames test   Carcinogeni- 
city test 
  Test Result Test Result Test Result Test Result 
                  
CID_45
39974 
Molecular 
fomula 
C12H16FN3
O3S 
Human 
Intestinal 
absorbtion 
92.52273 Ames 
 TA100 (+S9) 
 -ve Mo-
use 
 -ve 
  Molecular 
weight 
301.09 Caco-2 cell 
permeability 
4.27 Ames  
TA100 (-S9) 
 -ve Rat  -ve 
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  No. of 
HBA 
5 MDCK cell 
permeability 
1.28573 Ames 
TA1535(+S9) 
 +ve     
  No. of 
HBD 
3 Skin 
permeability 
-4.85983 Ames 
TA1535 (-S9) 
 -ve     
  LogP 0.44 Plasma protein 
binding 
46.13246 Ames  
TA98 (+S9) 
 -ve     
  Logs -3.23 BBB 
penetration 
0.14819 Ames  
TA98 (-S9) 
 -ve     
  TPSA 80.79 A2             
  Volume 259.58 A3             
 
 Table 8: Molsoft and PreADMET analysis of CID_3642762: 
  Molecular properties ADME properties Toxicity testing 
          Ames test   Carcinogeni- 
city test 
  Test Result Test Result Test Result Test Result 
                  
CID_36
42762 
Molecular 
fomula 
C12H15N5
O2S 
Human 
Intestinal 
absorbtion 
97.49478 Ames  
TA100 (+S9) 
 -ve Mo-
use 
 -ve 
  Molecular 
weight 
293.09 Caco-2 cell 
permeability 
17.2673 Ames 
 TA100 (-S9) 
 +ve Rat  -ve 
  No. of HBA 6 MDCK cell 
permeability 
8.66081 Ames  
TA1535 (+S9) 
 +ve     
  No. of HBD 0 Skin 
permeability 
-3.64644 Ames 
TA1535 (-S9) 
 -ve     
  LogP 1.59 Plasma protein 
binding 
47.80738 Ames 
 TA98 (+S9) 
 +ve     
  Logs -2.82 BBB 
penetration 
0.261164 Ames  
TA98 (-S9) 
 -ve     
  TPSA 71.71 A2             
  Volume 255.20A3             
 
Table 9: Molsoft and PreADMET analysis of CID_4268983: 
  Molecular properties ADME properties Toxicity testing 
          Ames test   Carcinogeni- 
city test 
  Test Result Test Result Test Result Test Result 
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CID_42
68983 
Molecular 
fomula 
C13H19N3
O4S 
Human 
Intestinal 
absorbtion 
91.02455 Ames  
TA100 (+S9) 
 -ve Mo-
use 
 -ve 
  Molecular 
weight 
313.11 Caco-2 cell 
permeability 
10.2067 Ames  
TA100 (-S9) 
 -ve Rat  -ve 
  No. of 
HBA 
3 MDCK cell 
permeability 
2.45932 Ames  
TA1535(+S9) 
 +ve     
  No. of 
HBD 
3 Skin 
permeability 
-4.5932 Ames  
TA1535 (-S9) 
 -ve     
  LogP 0.26 Plasma protein 
binding 
28.07151 Ames  
TA98 (+S9) 
 -ve     
  Logs -3.09 BBB 
penetration 
0.109841 Ames  
TA98 (-S9) 
 -ve     
  TPSA 88.40 A2             
  Volume 285.56 A3             
 
The properties of the best 3 molecules are predicted from the above table. The predicted 
properties are listed below: 
 
Table 10: Prediction of properties of molecules 
Properties Molecule  
  
          CID_4539974   CID_3642762    CID_4268983    
Molecular Deviation from lipinski 
rule 
    0   0   0   
                      
ADME   Human Intestinal 
absorbtion 
    Well   Well   Well   
    Caco-2 cell permeability     Moderate Moderate   Moderate 
    MDCK cell permeability     Low   Low   Low   
    Plasma protein binding     Weakly bound Weakly bound Weakly bound 
    BBB penetration   Inactive   Inactive   Inactive   
                      
Toxicity   AMES     Negative   Positive   Negative   
    Carcinogenicitty     Negative   Negative   Negative   
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The above table demonstrate the properties of molecule as a potent drug candidate. None of 
molecule out of three violates the Lipinski rule of five. All molecules have well human intestinal 
absorption, moderate Caco-2 cell permeability, low MDCK cell permeability, weakly bound to 
plasma protein and inactive BBB penetration. None of these molecule show carcinogenicity and 
only one molecule CID_3642762 show positive AMES test. This result depicts that two 
molecules CID_4539974 and CID_4268983 have all desirable properties to be a drug. 
Combining   and analyzing this result with docking and H-bond analysis result, 1-(4-
fluorophenyl)sulfonylpiperidine-3-carbohydrazide (CID_4539974) showed to be a best potent 
PDI with having best docking result, inhibiting PDF of all selected microorganism, best H-bond 
analysis result, makes H-bond with active metal binding amino acid residue of PDF in all 
bacteria and containing all properties of drug molecule. Therefore, CID_4539974 was sorted as a 
best drug candidate out of 118 isomers of sulfonylpiperidine and selected for pharmacophore 
modelling and molecular dynamics simulation to study protein-ligand stability in biological 
system using GROMACS. 
 
4.7 Pharmacophore modelling of CID_4539974-PDF Complex 
Pharmacophore modelling was done to identify the key features on the ligand which are 
interacting with points on the protein. It was done for two protein-ligand complex. One for PDF 
of S.Mutans (3L87) with which CID_4539974 gave highest binding energy of -8.75kcal/mol and 
other for PDF of E.Coli (1BSK) with which CID_4539974 gave lowest binding energy of -10.54 
kcal/mol. 
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3L87-CID_4539974 complex 3-D view 3L87-CID_4539974 complex 2-D view 
 
  
1BSK-CID4539974 complex 3-D view 1BSK-CID4539974 complex 2-D view 
 
Figure 21: 3-D and 2-D pharmacophore model of 3L87-CID_4539974 complex and 1BSK- 
                 CID4539974 complex respectively. 
The pharmacophore model of 3L87-CID_4539974 shows 2 H-Bond donors and 2 H-Bond 
acceptor. Leu132 is neighbour of active metal binding amino acid residue Cys131. While the 
pharmacophore model of 1BSK-CID_4539974 shows 1 H-Bond donors and 4 H-Bond acceptor. 
Cys90 is active metal binding amino acid residue. 
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4.8 Molecular Dynamics Simulation of CID_4539974-PDF Complex: 
Molecular dynamics simulation was run to study the stability of complex i.e. CID_4539974-PDF 
in biological system. This computational method calculated the time dependent behaviour of 
protein-ligand complex. Molecular Dynamics simulation has provided detailed information on 
the fluctuations and conformational changes of PDF. In order to validate our ligand first the PDF 
enzyme alone and then PDF-CID_4539974 complex was subjected to exhaustive a 1ns 
equilibrated Molecular Dynamics Simulation. System total energy, root mean square deviation 
(RMSD) and root mean square fluctuation (RMSF) file were generated for both protein alone 
and protein-ligand complex. MD simulation was run for two protein-ligand complex. One for 
PDF of S.Mutans (3L87) with which CID_4539974 gave lowest binding energy of -8.75kcal/mol 
and other for PDF of E.Coli (1BSK) with which CID_4539974 gave highest binding energy of -
10.54 kcal/mol. We selected these two because on the basis of their result we can predict the 
simulation properties of remaining six protein-ligand complexes. All the results are shown in 
figure below: 
 
4.8.1 Gromacs energies result: 
  
3L87 alone 3L87 – CID_4539974 complex 
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1BSK alone 1BSK-CID4539974 complex 
 
Figure 22: System energy of PDF (3L87 and 1BSK) without and with CID_4539974 
The above Gromacs energies result shows that the total energy of the system remains almost 
constant after the binding of ligand with protein. Figure on the left side shows system energy of 
3L87 and 1BSK when they were not bound with ligand while the figure on the right side 
represents the system energy of protein-ligand complex.  The binding of ligand with protein does 
not cause significant change in system energy. For 3L87, the total energy of the system remains 
constant and fluctuates around -4.2 × 10
5
 kJ/mol before and after binding of ligand, while for 
1BSK, the total energy of system remains constant and fluctuates around -3.8 × 10
5
 kJ/mol 
before and after binding of ligand. 
 
4.8.2 Gromacs Root Mean Square Deviation (RMSD) results: 
  
3L87 alone 3L87 – CID_4539974 
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1BSK alone 1BSK-CID4539974 complex 
 
Figure 23: RMSD with respect to simulation time of 1ns for 3L87 and 1BSK with and without 
                  CID_4539974 
 
  
3L87 vs 3L87-CID_4539974 complex 1BSK vs 1BSK-CID_4539974 complex 
 
Figure 24: Superposition of RMSD of 3L87 with 3L87-CID_4539974 complex and 1BSK with 
                 1BSK-CID_4539974 complex. 
Figure 23 shows the evolution of RMSD of Cα from the crystal structure during MD simulation. 
The protein atoms do not significantly deviate from the crystal structure and the Cα RMSD is 
stabilized to an average value of 0.022 ± .002 nm in both 3L87 and 1BSK before and after 
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binding of ligand. This result is well agreement with the result of figure y. In figure 24, 
superposition of RMSD of 3L87 with 3L87-CID_4539974 (left) and 1BSK with 1BSK-
CID_4539974 complex (right) was done. Superposition shows there is negligible deviation in 
RMSD after binding of ligand with enzyme. 
 
4.8.3 Gromacs Root Mean Square Fluctuation (RMSF) results: 
  
3L87 alone 3L87 – CID_4539974 
 
  
1BSK alone 1BSK-CID4539974 complex 
 
Figure 25: RMSF with respect to residue during MD simulation for 3L87 and 1BSK with and 
                 without ligand. 
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3L87 vs 3L87-CID_4539974 complex 1BSK vs 1BSK-CID_4539974 complex 
 
Figure 26: Superposition of RMSF of 3L87 with 3L87-CID_4539974 complex and 1BSK with 
                 1BSK-CID_4539974 complex. 
The flexibilities of the proteins were considered by the RMSF values obtained from conventional 
MD simulations which reflect the flexibility of each amino acid residue in the protein. Figure 25, 
shows the RMSF of the backbone of 3L87 and 1BSK with and without ligand as a function of 
residue number. The results indicate that the major fluctuations of residues occur in loops region 
connecting secondary structure elements. These residues are located in the exterior area of 
protein, and correspond to the regions of protein with large RMSD. In a characteristic RMSF 
pattern, a low RMSF value indicates the well-structured regions while the high values indicate 
the loosely structured loop regions or domains terminal. In the 3L87 and 1BSK major fluctuation 
occurs in region containing active metal binding amino acid residue i.e., Cys131 and Cys91 
respectively. 
In figure 26, superposition of RMSF graph of 3L87 with 3L87-CID_4539974 complex and 
1BSK with 1BSK-CID_4539974 complex shows that there is decrease in RMSF value after 
binding of ligand with enzyme. This result demonstrates the stability of PDF-ligand complex.  
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CHAPTER 5 
 
CONCLUSION  
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5. CONCLUSION 
 
5.1 Summary 
 In the current study, a novel inhibitor of bacterial PDF has been developed that can be 
used as a broad-spectrum antimicrobial since the active site of Peptide Deformylase that 
is composed of three sequence motifs, was confirmed to be conserved throughout the 
microorganism. 
 Since PDF is essential for bacterial survival but apparently not important for animal cell, 
it provides an attractive target for broad-spectrum antibacterial. 
 Since hydrazides have shown inhibitory properties for PDF, Sulfonylpiperidine, a 
hydrazine from the vast group of hydrazides, was considered for docking and the result 
confirmed its essential role in inhibiting PDF from high binding energy in all bacterial 
species tested. 
 Among the 118 ligands tested CID_4539974 was found to be in the best 5 list in all 
bacteria’s, CID_3642762 was found to be in the best 5 list in all except S. mutans (3L87) 
and S. aureus (1LQW), CID_4268983 was found to be in the best 5 list in all except P. 
aeruginosa (1N5N) and E.coli (1BSK). 
 CID_4539974, CID_3642762 and CID_4268983 were selected for H-bond analysis, 
molecular properties calculation and ADME & toxicity prediction. 
 The result obtained sorted 1-(4-fluorophenyl) sulfonylpiperidine-3-carbohydrazide 
(CID_4539974) to be best PDI out of three. 
 CID_4539974 made H-bond with active metal binding amino acid residue of all bacterial 
PDF, didn’t  deviate from Lipinski rule, and exhibited best inhibition affinity for PDF, 
good drug-likeness model score, optimal intestinal absorption, moderate Caco-2 cell 
permeability, week bound to plasma protein binding, inactive BBB penetration, negative 
AMES and carcinogenic property. 
 Finally, MD simulation checked the stability of protein-ligand complex under biological 
conditions and was run for highest and lowest binding energy protein-ligand complex of 
CID_4539974.  Kinetic energy, RMSD and RMSF graph confirmed the stability of PDF-
CID_4539974 complex in biological system. 
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5.2 Conclusion 
Lower binding energies and inhibition constant of CID_4539974 than actinonin concluded that it 
has better inhibitory properties than actinonin. The molecular, ADME and toxicity of 
CID_4539974 established it has drug like properties and could be a potent PDI (Peptide 
Deformylase Inhibitor). MD simulation concluded that PDF-CID_4539974 complex is stable 
under biological condition. All these outcomes interpret that CID_4539974 have all the 
properties to become a broad spectrum antibacterial by targeting bacterial PDF efficiently. 
 
5.3 Future perspectives 
Rising cost of drug development, increased bacterial resistance, emerging new diseases and lack 
of enough therapeutic agents have been a major concern in recent years. Therefore we need to 
alternative methods to get solutions on safety and efficacy faster and at lower cost. One such 
method is insilico drug designing. It plays significant role in all stages of drug development from 
preclinical stage to late clinical stage. In this modern era of Computer Aided Drug Design 
(CADD), a novel work is first started by virtual screening or insilico designing, and then goes for 
invitro and invivo analysis. Development of new drug is a sequential process start with insitu 
study, insilco drug design, invitro analysis and finally invivo testing. The availability of 
bioinformatics tools and software helped to identify probable antimicrobial drug to dock with 
protein targets. 
All the above findings are generated with the help of most reliable tools and software of 
computational biology. The ligands discussed in the current study need QSAR study before 
qualifying for in vitro analysis followed by clinical trial. Moreover, since the microorganism are 
fast gaining resistance to the existing drugs, the drug identified in the study,1-(4-fluorophenyl) 
sulfonylpiperidine-3-carbohydrazide (CID_4539974) can provide a better option for designing 
new drugs by modifying its chemical structure.  
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